Singapore's Minister for Health and Minister-in-Charge of Social Policies Ong Ye Kung Visits MindRank AI to Explore AI-Driven Drug Discovery Innovations

Jan 30, 2026 08:16 CST Updated 08:16

MindRank

AI Drug Developer

In the afternoon of January 28, Ong Ye Kung, Singapore's Minister for Health and Minister-in-charge of Social Policy, along with Chen Haiquan, Singapore's Ambassador to China, visited MindRank Ltd. headquarters in Hangzhou for inspection and guidance.MindRankFounder and CEO Zhangming Niu accompanied the company's core team throughout the visit.

A delegation from the Singapore Ministry of Health visitedMindRankHangzhou R&D Base and held discussions with the MindRank team.

At the symposium,MindRankFounder and CEO Zhangming Niu introduced the company's application of artificial intelligence in innovative drug research and development, as well as the latest R&D achievements. Starting from the upstream demands of drug research and development,MindRankRelying on the self-developed Molecule Pro™ platform, through continuous technological innovation and algorithm iteration, to improve the efficiency and success rate of new drug research and development while reducing R&D costs. Its self-developed oral small molecule GLP-1 receptor agonist MDR-001 has entered Phase III clinical trials and has initiated in-depth cooperation with upstream and downstream pharmaceutical companies.

Minister Wang Yijian and his entourage visitedMindRankAt the Hangzhou headquarters, learn how the company conducts work in AI-assisted new drug development. The two parties exchanged views on the technology of the AI drug discovery platform, the progress of candidate drugs, data management, and policy regulation.

In the future, the company will continue to promote the deep integration of AI technology and new drug research and development, contributing innovative solutions to global health.

END

MindRank Paper | AI Empowers Scientific Research Boom! Multiple Significant Achievements Published in International Top Journals, Unlocking New Paths for Anti-Aging and Innovative Drug Development

MindRank AI-Assisted Design of Oral Small Molecule Weight Loss Drug MDR-001 Enters Phase III Clinical Trial

24 Weeks, 10.3% Weight Loss! MindRank's First AI-Designed Small Molecule GLP-1 Receptor Agonist MDR-001 Achieves Success in Phase IIb Clinical Trial

IND Approved | MindRank's Self-developed WEE1/YES1 Dual Inhibitor Receives FDA Clinical Approval

MindRank Completes Over $20 Million Series A+ Financing to Accelerate Advancement of Innovative Drug Pipeline and AI Platform Commercialization

For more information, please visit the website:

www.mindrank.ai

Contact: bd@mindrank.ai pr@mindrank.ai

Other: info@mindrank.ai